Collaborative Arrangements (Tables)

12 Months Ended

Dec. 31, 2014

Collaborative Arrangements

Collaborator revenues

During the three years ended December 31, 2014, the Company recognized the following revenues attributable to the Janssen HCV collaboration:

	2014		2013		2012
	(in thousands)
Royalty revenues	$	13,481	$	130,724	$	117,592
Collaborative revenues:
Up-front and amendment payments revenues	$	—	$	190,345	$	12,428
Net reimbursement (payment) for telaprevir development costs	7,104		2,793		(3,507		)
Reimbursement for manufacturing services	—		10,299		7,257
Total collaborative revenues attributable to the Janssen HCV collaboration	$	7,104	$	203,437	$	16,178
Total revenues attributable to the Janssen HCV collaboration	$	20,585	$	334,161	$	133,770

Summary of activity related to net loss (income) attributable to noncontrolling interest (Alios)

A summary of Alios’ net loss (income) attributable to noncontrolling interest for 2012 and 2013 is as follows:

	2013			2012
	(in thousands)
Loss before provision for (benefit from) income taxes	$	283,747		$	20,044
Decrease (increase) in fair value of contingent milestone and royalty payments	124,920			(114,970		)
Provision for (benefit from) income taxes	(166,145		)	39,029
Net loss (income) attributable to noncontrolling interest (Alios)	$	242,522		$	(55,897	)